Eliezer Van Allen

Eliezer Van Allen applies machine learning and computational genomics to develop predictive models for immunotherapy response, including whole-exome sequencing-based biomarkers predicting anti-PD-1 benefit across tumor types. His landmark studies have revealed genomic determinants of IO response and resistance including tumor mutational burden, BRCA mutations, and epigenetic biomarkers. He contributes to the Foundation for Precision Cancer Medicine and leads translational genomics programs across multiple tumor types. Van Allen is one of the most innovative computational oncologists working at the interface of genomics, immunology, and clinical IO.